Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling

Chang Joo Oh, Joon Young Kim, Ae Kyung Min, Keun Gyu Park, Robert A. Harris, Han Jong Kim, In Kyu Lee

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Sulforaphane (SFN) is a dietary isothiocyanate that exerts chemopreventive effects via NF-E2-related factor 2 (Nrf2)-mediated induction of antioxidant/phase II enzymes, such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). This work was undertaken to evaluate the effects of SFN on hepatic fibrosis and profibrotic transforming growth factor (TGF)-β/Smad signaling, which are closely associated with oxidative stress. SFN suppressed TGF-β-enhanced expression of α-smooth muscle actin (α-SMA), a marker of hepatic stellate cell (HSC) activation, and profibrogenic genes such as type I collagen, fibronectin, tissue inhibitor of matrix metalloproteinase (TIMP)-1, and plasminogen activator inhibitor (PAI)-1 in hTERT, an immortalized human HSC line. SFN inhibited TGF-β-stimulated activity of a PAI-1 promoter construct and (CAGA) 9 MLP-Luc, an artificial Smad3/4-specific reporter, in addition to reducing phosphorylation and nuclear translocation of Smad3. Nrf2 overexpression was sufficient to inhibit the TGF-β/Smad signaling and PAI-1 expression. Conversely, knockdown of Nrf2, but not inhibition of HO-1 or NQO1 activity, significantly abolished the inhibitory effect of SFN on (CAGA) 9 MLP-Luc activity. However, inhibition of NQO1 activity reversed repression of TGF-β- stimulated expression of type I collagen by SFN, suggesting the involvement of antioxidant activity of SFN in the suppression of Smad-independent fibrogenic gene expression. Finally, SFN treatment attenuated the development and progression of early stage hepatic fibrosis induced by bile duct ligation in mice, accompanied by reduced expression of type I collagen and α-SMA. Collectively, these results show that SFN elicits an antifibrotic effect on hepatic fibrosis through Nrf2-mediated inhibition of the TGF-β/Smad signaling and subsequent suppression of HSC activation and fibrogenic gene expression.

Original languageEnglish (US)
Pages (from-to)671-682
Number of pages12
JournalFree Radical Biology and Medicine
Volume52
Issue number3
DOIs
StatePublished - Feb 1 2012

Fingerprint

NF-E2-Related Factor 2
Transforming Growth Factors
Fibrosis
Liver
Hepatic Stellate Cells
Plasminogen Activator Inhibitor 1
Collagen Type I
Heme Oxygenase-1
Gene expression
Antioxidants
Chemical activation
Gene Expression
sulforafan
Matrix Metalloproteinase 1
Phosphorylation
Tissue Inhibitor of Metalloproteinase-1
Oxidative stress
Bile Ducts
Fibronectins
NAD

Keywords

  • Antioxidant genes
  • Free radicals
  • Hepatic fibrosis
  • Nrf2
  • Sulforaphane
  • TGF-β/Smad signaling pathway

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)

Cite this

Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. / Oh, Chang Joo; Kim, Joon Young; Min, Ae Kyung; Park, Keun Gyu; Harris, Robert A.; Kim, Han Jong; Lee, In Kyu.

In: Free Radical Biology and Medicine, Vol. 52, No. 3, 01.02.2012, p. 671-682.

Research output: Contribution to journalArticle

Oh, Chang Joo ; Kim, Joon Young ; Min, Ae Kyung ; Park, Keun Gyu ; Harris, Robert A. ; Kim, Han Jong ; Lee, In Kyu. / Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. In: Free Radical Biology and Medicine. 2012 ; Vol. 52, No. 3. pp. 671-682.
@article{4cfb1ba81b4e4c98bf60617f672c0acd,
title = "Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling",
abstract = "Sulforaphane (SFN) is a dietary isothiocyanate that exerts chemopreventive effects via NF-E2-related factor 2 (Nrf2)-mediated induction of antioxidant/phase II enzymes, such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). This work was undertaken to evaluate the effects of SFN on hepatic fibrosis and profibrotic transforming growth factor (TGF)-β/Smad signaling, which are closely associated with oxidative stress. SFN suppressed TGF-β-enhanced expression of α-smooth muscle actin (α-SMA), a marker of hepatic stellate cell (HSC) activation, and profibrogenic genes such as type I collagen, fibronectin, tissue inhibitor of matrix metalloproteinase (TIMP)-1, and plasminogen activator inhibitor (PAI)-1 in hTERT, an immortalized human HSC line. SFN inhibited TGF-β-stimulated activity of a PAI-1 promoter construct and (CAGA) 9 MLP-Luc, an artificial Smad3/4-specific reporter, in addition to reducing phosphorylation and nuclear translocation of Smad3. Nrf2 overexpression was sufficient to inhibit the TGF-β/Smad signaling and PAI-1 expression. Conversely, knockdown of Nrf2, but not inhibition of HO-1 or NQO1 activity, significantly abolished the inhibitory effect of SFN on (CAGA) 9 MLP-Luc activity. However, inhibition of NQO1 activity reversed repression of TGF-β- stimulated expression of type I collagen by SFN, suggesting the involvement of antioxidant activity of SFN in the suppression of Smad-independent fibrogenic gene expression. Finally, SFN treatment attenuated the development and progression of early stage hepatic fibrosis induced by bile duct ligation in mice, accompanied by reduced expression of type I collagen and α-SMA. Collectively, these results show that SFN elicits an antifibrotic effect on hepatic fibrosis through Nrf2-mediated inhibition of the TGF-β/Smad signaling and subsequent suppression of HSC activation and fibrogenic gene expression.",
keywords = "Antioxidant genes, Free radicals, Hepatic fibrosis, Nrf2, Sulforaphane, TGF-β/Smad signaling pathway",
author = "Oh, {Chang Joo} and Kim, {Joon Young} and Min, {Ae Kyung} and Park, {Keun Gyu} and Harris, {Robert A.} and Kim, {Han Jong} and Lee, {In Kyu}",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.freeradbiomed.2011.11.012",
language = "English (US)",
volume = "52",
pages = "671--682",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling

AU - Oh, Chang Joo

AU - Kim, Joon Young

AU - Min, Ae Kyung

AU - Park, Keun Gyu

AU - Harris, Robert A.

AU - Kim, Han Jong

AU - Lee, In Kyu

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Sulforaphane (SFN) is a dietary isothiocyanate that exerts chemopreventive effects via NF-E2-related factor 2 (Nrf2)-mediated induction of antioxidant/phase II enzymes, such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). This work was undertaken to evaluate the effects of SFN on hepatic fibrosis and profibrotic transforming growth factor (TGF)-β/Smad signaling, which are closely associated with oxidative stress. SFN suppressed TGF-β-enhanced expression of α-smooth muscle actin (α-SMA), a marker of hepatic stellate cell (HSC) activation, and profibrogenic genes such as type I collagen, fibronectin, tissue inhibitor of matrix metalloproteinase (TIMP)-1, and plasminogen activator inhibitor (PAI)-1 in hTERT, an immortalized human HSC line. SFN inhibited TGF-β-stimulated activity of a PAI-1 promoter construct and (CAGA) 9 MLP-Luc, an artificial Smad3/4-specific reporter, in addition to reducing phosphorylation and nuclear translocation of Smad3. Nrf2 overexpression was sufficient to inhibit the TGF-β/Smad signaling and PAI-1 expression. Conversely, knockdown of Nrf2, but not inhibition of HO-1 or NQO1 activity, significantly abolished the inhibitory effect of SFN on (CAGA) 9 MLP-Luc activity. However, inhibition of NQO1 activity reversed repression of TGF-β- stimulated expression of type I collagen by SFN, suggesting the involvement of antioxidant activity of SFN in the suppression of Smad-independent fibrogenic gene expression. Finally, SFN treatment attenuated the development and progression of early stage hepatic fibrosis induced by bile duct ligation in mice, accompanied by reduced expression of type I collagen and α-SMA. Collectively, these results show that SFN elicits an antifibrotic effect on hepatic fibrosis through Nrf2-mediated inhibition of the TGF-β/Smad signaling and subsequent suppression of HSC activation and fibrogenic gene expression.

AB - Sulforaphane (SFN) is a dietary isothiocyanate that exerts chemopreventive effects via NF-E2-related factor 2 (Nrf2)-mediated induction of antioxidant/phase II enzymes, such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). This work was undertaken to evaluate the effects of SFN on hepatic fibrosis and profibrotic transforming growth factor (TGF)-β/Smad signaling, which are closely associated with oxidative stress. SFN suppressed TGF-β-enhanced expression of α-smooth muscle actin (α-SMA), a marker of hepatic stellate cell (HSC) activation, and profibrogenic genes such as type I collagen, fibronectin, tissue inhibitor of matrix metalloproteinase (TIMP)-1, and plasminogen activator inhibitor (PAI)-1 in hTERT, an immortalized human HSC line. SFN inhibited TGF-β-stimulated activity of a PAI-1 promoter construct and (CAGA) 9 MLP-Luc, an artificial Smad3/4-specific reporter, in addition to reducing phosphorylation and nuclear translocation of Smad3. Nrf2 overexpression was sufficient to inhibit the TGF-β/Smad signaling and PAI-1 expression. Conversely, knockdown of Nrf2, but not inhibition of HO-1 or NQO1 activity, significantly abolished the inhibitory effect of SFN on (CAGA) 9 MLP-Luc activity. However, inhibition of NQO1 activity reversed repression of TGF-β- stimulated expression of type I collagen by SFN, suggesting the involvement of antioxidant activity of SFN in the suppression of Smad-independent fibrogenic gene expression. Finally, SFN treatment attenuated the development and progression of early stage hepatic fibrosis induced by bile duct ligation in mice, accompanied by reduced expression of type I collagen and α-SMA. Collectively, these results show that SFN elicits an antifibrotic effect on hepatic fibrosis through Nrf2-mediated inhibition of the TGF-β/Smad signaling and subsequent suppression of HSC activation and fibrogenic gene expression.

KW - Antioxidant genes

KW - Free radicals

KW - Hepatic fibrosis

KW - Nrf2

KW - Sulforaphane

KW - TGF-β/Smad signaling pathway

UR - http://www.scopus.com/inward/record.url?scp=84856302591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856302591&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2011.11.012

DO - 10.1016/j.freeradbiomed.2011.11.012

M3 - Article

C2 - 22155056

AN - SCOPUS:84856302591

VL - 52

SP - 671

EP - 682

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

IS - 3

ER -